doi: 10.1161/01.cir.94.3.258
95% CI: 3.79 to 1.29) and 1.0 mg subcutaneous semaglutide (WMD, 2.67, 95% CI: 3.99 to 1.34) (Fig
Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,
Importantly, routine thyroid function testing is not required by the label, though Zepbound is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2
It's a simple way to support your weight loss progressespecially when combined with healthy eating and regular movement